Please ensure Javascript is enabled for purposes of website accessibility

Why Intercept Pharmaceuticals Is Plunging Today

By Prosper Junior Bakiny – May 22, 2020 at 11:54AM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The company received some bad news from the FDA.

What happened?

Shares of Intercept Pharmaceuticals (ICPT 4.53%) are plunging on Friday after the company announced some bad news regarding its new drug application (NDA) for Ocaliva as a treatment for fibrosis (buildup of scar tissue) in the liver due to nonalcoholic steatohepatitis (NASH). Intercept's shares are down by 14.4% as of 11:34 a.m. today. 

So what

Intercept submitted an NDA to the U.S. Food and Drug Administration (FDA) for Ocaliva as a treatment for fibrosis due to NASH back in September 2019, and Ocaliva was granted priority review by the health industry regulator. Also, the FDA tentatively scheduled an advisory committee meeting regarding this application for June 9, 2020. Today Intercept announced that the FDA has decided to postpone this meeting indefinitely. This decision by the FDA will delay the approval process for Ocaliva as a treatment for fibrosis due to NASH.

Five downward pointing arrows on a blackboard.

Image source: Getty Images.

Now what

Intercept has a lot riding on this application. Ocaliva is the company's only approved product at the moment, and although it is generating growing revenue -- sales of Ocaliva grew by 40% year over year to $72.7 million during the first quarter -- a new indication for this drug would help Intercept further boost its revenue and earnings. The pharma company estimates that there are about 19 million NASH patients in the U.S., and about 16 million of them suffer from fibrosis.

And considering there are currently no FDA-approved treatments for fibrosis due to NASH, Intercept's revenue could increase significantly once it receives approval for this indication. Even with today's setback, though, Intercept looks likely to earn FDA approval for Ocaliva as a treatment for fibrosis due to NASH, and the company's losses on the market may represent an opportunity for investors. 

Prosper Junior Bakiny has no position in any of the stocks mentioned. The Motley Fool recommends Intercept Pharmaceuticals. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Intercept Pharmaceuticals Stock Quote
Intercept Pharmaceuticals
ICPT
$14.09 (4.53%) $0.61

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
331%
 
S&P 500 Returns
106%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 10/04/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.